Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G

Overview

  • EPIC Code:
  • LAB2639
  • Soft Test Code:
  • Send Out Test Code:
  • 11368
Alternate Names
  • 4G5G
  • PAI-1 4G/5G
  • Plasminogen Activator Inhibitor-1 4G/5G
Clinical Significance

Plasma plasminogen activator inhibitor, PAI-1 is a major inhibitor of fibrinolysis. The 4G variant (AF386492.2:g.837del) in the PAI-1 (Serpine 1) gene promoter region is associated with an increase in the level of PAI-1 in plasma. Increased levels of PAI-1 in plasma may increase the risk for arterial and venous thrombosis, myocardial infarction, and progression of atherosclerosis and also recurrent spontaneous abortion.


Specimen Collection & Preparation

Specimen Requirements

5.0 mL Whole Blood in a Lavender Top Tube - EDTA


Transport And Storage

8 days Ambient  (transport)
8 days Refrigerated


Collection Instructions

 


Minimum Volume

3.0 mL Whole Blood


Neonatal Volume

Clinical Interpretation

Reference Range:

Refer to Interpretive Results


Methodology:
  • Detection
  • Polymerase Chain Reaction (PCR)
Clinical Significance

Plasma plasminogen activator inhibitor, PAI-1 is a major inhibitor of fibrinolysis. The 4G variant (AF386492.2:g.837del) in the PAI-1 (Serpine 1) gene promoter region is associated with an increase in the level of PAI-1 in plasma. Increased levels of PAI-1 in plasma may increase the risk for arterial and venous thrombosis, myocardial infarction, and progression of atherosclerosis and also recurrent spontaneous abortion.


Production Schedule

Sites Performed
  • Quest - Chantilly to San Juan Capistrano
Days Performed
Wednesday
Departments
  • Sendouts - Clinical
Turn Around Time

12 to 18 days


Coding & Compliance

CDM

00913006


CPT Coding

81400